Try our Advanced Search for more refined results
Life Sciences - November, 2018
265 articles
- Class Action Rule Changes Target 'Professional Objectors'
- Immunotherapy Co. Hits Ch. 11 With $21M In Debt
- 11th Circ. OKs Indictment Change In Med-Smuggling Case
- Medtronic Owes Ind. Surgeon $112M In Royalties, Jury Finds
- Aralez Creditors Slam Proposed Ch. 11 Sales To Deerfield
- Fed. Circ. Won't Shield Atty Emails For Thermo Fisher Unit
- DOJ Will Nuke Gilead FCA Suit, Supreme Court Hears
- 8 Firms To Guide 4 IPOs Led By $500M Biotech Deal
- Pa. Judge Won't Revive Xarelto Suit Despite Patient's Death
- Monsanto Objects To Dying Man's Bid For A Quick Trial
- Becton Buyers' Antitrust Suit Killed Under Illinois Brick
- Société Générale: Sanctions Enforcement Is Alive And Well
- Gov't Wants Insys Founder's Atty Sanctioned For Media Talk
- Health Hires: Foley, Smith Gambrell, NewYork-Presbyterian
- What High Court Will Consider In Helsinn On-Sale Bar Case
- Dickinson Wright Nabs 6 IP Attys In Florida, Calif., DC
- Mass. US Atty Sends Warnings To Opioid-Prescribing Docs
- Fund Manager Tries To Duck Valeant Insider Trading Claims
- Pfizer Loses PTAB Challenge To Antibody Drug Patents
- Fla. Pharmacist Gets 6½ Years For Bogus Claims For Creams
- Pet Med Distributors Can't Access PetIQ's Merger Filings
- PTAB Upholds Patent For Akorn Glaucoma Drug Zioptan
- Sterigenics Suits Belong In State Court, Ill. Residents Say
- Insys Founder Must Turn Over Docs In Opioid Probe, Feds Say
- 5 Mos. Sought For Biotech Exec Who Pled Guilty After Mistrial
- JPML Wary Of Special Litigation For 'Opioid Babies'
- New CMS Rules Reinforce Trend Away From Traditional Care
- In Hip Implant MDL, Preemption Cuts Across State Lines
- 3rd Circ. Upholds Case Transfer Limits On Bankruptcy Courts
- Mylan Asks Supreme Court To Rein In 'Tactical' Drug Patenting
- Ex-Zimmer Exec Loses Benefits Bid In Sex Discrimination Suit
- 2 Attys Charged, Face SEC Suit Over Pump & Dump Scheme
- Mylan Pushes For Consumer Witnesses In Battle With Celgene
- AbbVie Tries To Ax Investor Suit Over $100M Stock Drop
- Deals Rumor Mill: Sears, Murphy Oil, GSK
- Med Tech Co. Seeks DC Circ. Review Of $400M Award Denial
- Drug Co. Can't Duck Opioid Questions In Pay-For-Delay Suit
- FDA Approves First Non-Hodgkin's Lymphoma Biosimilar
- Goodwin-Led Biotech Co. Moderna Sets Sights On $500M IPO
- Merck Tells Justices Misconduct Doesn't Nix $200M IP Award
- Full Fed. Circ. Asked To Skip 'Blocking Patent' Case
- Insys Ex-VP To Cooperate With Gov't In Opioid Kickback Case
- Eli Lilly Wins Stay In Eagle Antitrust Suit Amid Patent Fight
- HHS OIG Opinion Raises Questions On Free Drug Offers
- DLA Piper Fights DQ Bid In Hemophilia Treatment Row
- Justices Weigh Missed Deadline In Nutraceutical False Ad Suit
- Phigenix Fights $2.2M Atty Fee Bid In Cancer Drug IP Row
- FDA Focus: What Arnold & Porter's Practice Chair Is Watching
- WARF Hit With $32M Bill Over WashU Royalty Sharing
- Biotech Co. Nuredis Sued Over Board Members' Legal Costs
- 3rd Circ. Says Doc's TCPA Claims Against Sanofi Are Untimely
- Express Scripts Urges Toss Of Records Fee Suit
- Irish Genomics Research Co. Inks $400M Investment
- Jurors Should Ask More Questions During Trials
- The Narrow Meaning Of Asacol Class Action Ruling
- 9th Circ. Won't Revisit FCA Materiality Dispute
- Big Pharma Howls As Feds Eye Wider Drug Negotiations
- Cloud Co. Can't Beat Suit Over Drug-Testing Software IP
- 32 States Back Ark. In Potential High Court Drug-Price Fight
- Federal Insurance Beats Suit Over Denial Of Life Policy Claim
- Ex-PTAB Chief Fires Back At Medtronic In Gay Bias Case
- Deals Rumor Mill: Bayer, Fiat, Total
- Forward Seeks 2nd Fed. Circ. Look At MS Drug Patent Case
- FDA Modernizes Medical Device Review Process
- DLA Piper Nabs Life Sciences Pro From Goodwin
- Calif. Ruling Dings Engagement Letter Arbitration Clauses
- Pa. Mesh Judge Won't Recuse Over Mom's Case Against J&J
- 10 Things We Wish We Were Told When Going In-House
- California Tax Takes: Tax Ballot Initiative Constitutionality
- Fed. Circ. Is Tightening Appellate Standing For IPR Cases
- Law360 MVP Awards Go To Top Attorneys From 71 Firms
- Perrigo Wants To Nix Investor Suits Over Failed Mylan Buyout
- UK Co. Says Abbott Can't Tie It To 'Gray Market' Scheme
- Rite Aid Escapes Generic Drug Copay Suit Over Timeliness
- FDA Finally Hitting Sweet Spot With Off-Label Oversight
- Drug Cos. Hit With $18M False Ad Verdict Over Probiotic IP
- Drug Cos. Can't Block Damages In Opioid MDL Bellwethers
- Janssen Turns To High Court In Bid To Block Zytiga Generics
- Consumer Groups Push 1st Circ. To Redo Asacol Class Cert.
- Taxation With Representation: Latham, Wachtell, Kirkland
- More Medical Device Co. Inspections Upped Compliance: FDA
- Sanofi Tells Justices To Pass On Appeal Over Repatha IP
- 3 Firms Vie To Lead Class Suit Over Alleged AbbVie Kickbacks
- Up Next At High Court: Apple's App Store, Civil Forfeiture
- Taiwanese Biotech Tops 3 IPOs Totaling $46M In Short Week
- The Virtual Law Team: Advantages For Litigants And Lawyers
- Deals Rumor Mill: Carlyle, Lumenis, Babytree Group
- Teva Execs Liable For Price-Hike Misstatements: Investors
- Why Biotech And Pharma Patents Survive IPR
- What Does A Split Congress Mean For Drug Pricing Agenda?
- Dr. Reddy's, Mylan Win Challenge To Arthritis Drug Patents
- Fed. Circ. Says Analysis Lacking In Nix Of Quillivant IP
- J&J Again Asks Pa. Mesh Judge To Recuse Over Family Ties
- Pension Fund Slams Firm's Bid To Shed Valeant Fraud Suit
- Fed. Circ. Lifts Block On Dr. Reddy's Suboxone Generic
- $16M Deal OK'd In Zicam Cold Meds False Ad Class Suit
- Feds Want At Least 5 Yrs For Pharma CEO's $2M Drug Fraud
- Tokai Investor Marks Underwriters Liable In $10.8M Suit
- Breast Implant CEO Slams SEC's Stock Fraud 'Scheme' Claim
- Ex-Aveo CFO Found Liable For Misleading Investors
- GSK, Ex-Workers Battle For Quick Wins In Severance Fight
- Former Teva Exec Nabs $6.2M Bias Verdict After Firing
- EU Approves Takeda's £46B Shire Deal With Drug Sale
- Smith & Nephew Ditches Untimely Hip Implant Cases In MDL
- Fed. Circ. Won't Revisit Whether Catalog Dooms Dental Patent
- Saul Ewing Adds IP, Life Sciences Partners In Boston
- Shearman & Sterling Reps Boston Scientific In £3.3B BTG Buy
- Emerging Cybersecurity Threats In The Legal Industry
- Mallinckrodt Urges Court To Toss Investor Suit Over Acthar
- Free Mallinckrodt Drugs Risk Kickback Fines, Watchdog Says
- Justices Won't Hear Challenge To Fed. Circ. Drug Patent Test
- New Express Scripts Policy Merits Suit Revival, Court Told
- Blood-Clot Drug Buyers Seek Class Cert. In Antitrust Suit
- States, Feds Debate Birth Control Mandate Row's Next Step
- 4 Cos. Eye December IPOs With New Filings Totaling $350M
- Bankrupt Aralez Can Pay Execs Up To $4M In Work Bonuses
- Kirkland, Simpson Steer $3.15B Colfax-DJO Global Deal
- Pharma Cos. Sued Over Children Born Addicted To Opioids
- PTAB Invalidates Antecip's Bone Treatment Patent
- Medtronic Unit Agrees To $54.5M Deal In Investor Fraud Suit
- Accountant Denied Retrial Over $18M Biotech VC Fraud
- Supreme Court Will Address FCA Statute Of Limitations
- Rise Of The CMOs
- Alaska Native Health Group Added To Massive Opioid Suit
- Health Hires: Quinn Emanuel, Goodwin, Ropes & Gray
- Texas Man Convicted In $36M Drug Resale Scheme
- Deals Rumor Mill: Tesaro, Eli Lilly, Technicolor
- Can Canadians Enter US For Cannabis-Related Business?
- Calif. Judge Moves Up Roundup Trial Due To Health Concerns
- Goodwin Taps Ex-Gunderson Pro With Capital Markets Chops
- 2nd Mistrial Called On Claims J&J Talc Gave Atty Fatal Cancer
- Inside Trader Avoids Prison Time After Aiding Feds
- Pharma Cos. Must Hand Over Generic Restasis Plans In MDL
- Judge Won't Quash AGs' Subpoenas In Generic Pricing MDL
- Deals Rumor Mill: Centrexion, Dayco, JD Group
- Insys Sales VP To Plead Guilty In Opioid Kickback Case
- A Chat With Bryan Cave Innovation Chief Katie DeBord
- FDA Streamlines 510(k) Process, As Courts Reconsider It
- J&J Should Pay For Talc Devotee's Death, SC Jury Hears
- 9th Circ. Judge Doubts Bio-Rad Appeal Of Ex-GC's $11M Win
- Gibson Dunn Bows Out Of Pharma RICO Suit Amid DQ Bid
- Pfizer Debuts Biosimilar Of Amgen, Janssen Meds
- J&J Staves Off Asbestos Baby Powder Suit In Calif. Jury Win
- FTC Shuts Down 1-800 Contacts Online Ad Compacts
- Fed Circ. Won't Stay Immunity Ruling For Allergan's Appeal
- Bio-Rad Wins $24M Jury Verdict In 10X Genomics Patent Suit
- Pa. Panel Urged To Revive Risperdal Breast-Growth Case
- When A Patent Disclosure Is Not A Disclosure
- Ranbaxy Consumers Denied Cert. In Drug Contamination Suit
- Aveo CFO Testifies He Had Support For Disclosure Decisions
- Ropes & Gray Steers Medical Device Co.'s $56M IPO
- Allergan Cuts A Few State Claims In Restasis MDL
- Simple Secrets For Improving Your CLE
- 10 Firms Vie For Lead Counsel In Opko Health Fraud Row
- Express Scripts, Pharmacy Drama Ends With Last-Minute Deal
- Gottlieb Says FDA Acted Slowly On Opioids
- Imprimis Gets $100K Knocked Off Allergan Sanctions Bill
- Pharma Co. Shakes Texas Securities Suit In Post-Cyan Ruling
- Janssen 'Doublespeak' Fueled Opioid Crisis, NJ Suit Says
- Fed. Circ. Won't Restore Allergan's Restasis Patent Claims
- Teva Can't Escape Suit Over Price-Hike Statements: Investors
- Aveo Withheld FDA Rec From Investors, Ex-CFO Testifies
- Ex-CEO Accused Of Tipping Oriole Reaches $1.5M SEC Deal
- Investors Reach $12M Deal In Biotech Stock-Drop Case
- Ex-Merrimack Analyst Gets 6 Months For Insider Trading
- FDA Warns Stem Cell Co. On Marketing, Manufacturing
- AstraZeneca Inks $1.5B Sale Of US Respiratory Drug Rights
- It's Time For Law Firms To Start Talking About Gen Z
- Trump Picks Regulatory Czar For Kavanaugh's DC Circ. Seat
- Should Juries Try To Predict FDA Drug Labeling Decisions?
- Justices Won't Hear Cert. Dispute In Vitamin E Labeling Suit
- Fed. Circ. Tells PTAB To Look At NuVasive Patent Again
- Options Broker Must Stay In TIAA-Led Class In Valeant Suit
- Deals Rumor Mill: BlackBerry, Permira, ADM
- Express Scripts Rightfully Nixed Pharmacy Contract
- Judge OKs Release Of Market Share Data In Opioid MDL
- SEC Fights Priest's Bid To Skip $1.3M Short-Selling Suit
- Sens. Seek White House Backing For Pay-For-Delay Drug Bill
- 10 Firms To Guide 6 IPOs Exceeding $800M
- A Post-Election Survey Of The Health Care Ecosystem
- Homeopathic Co. Beats Consumer's Sugar Pill Claims
- Pharmaceutical Warnings: A Changing Landscape
- What To Expect From New Democratic Investigation Efforts
- Helsinn Tells Justices Teva 'Badly Misconstrues' On-Sale Bar
- New J&J Pelvic Mesh Trial Ordered In Pa.
- Anixa Investor Sues In Chancery Alleging Insider Stock Moves
- Del. Jury Finds Flexus Took Incyte Secrets, Nixes Damages
- Exforge Deal 'More Pernicious' Than Actavis, Court Told
- Back To School: Yale's Linda Greenhouse Talks Journalism
- Cooley Can Stay In Trade Secrets Suit Over Genomics Data
- McCarter & English Adds IP Duo In Boston
- Celebrate Veterans By Improving Their Access To Justice
- Blood-Pressure Drug Cos. Hit With Suit Over Contamination
- Patent And Copyright Changes In The New NAFTA
- Calif. Appeals Panel Revives Suits Over Diabetes Drugs
- Gibson Dunn Must Comply With Subpoena, Al Jazeera Says
- Fed. Circ. Upholds PTAB Nix Of Blood-Clotting Patent
- Investors Sue Akorn After Failed Merger 'Debacle' Kills Stock
- Medicaid Rebate Suit Not Barred By Similar Suits: Ex-Exec
- Biopharma Co. Hit With Suit Over Directors' 'Excessive' Pay
- Local Gov'ts Press For Opioid Market Share Data
- Fresenius Bid To Save Diprivan Patent Denied By Fed. Circ.
- Ranbaxy Abused Generic Drug Application Process, Suit Says
- Pharma Biz Nabs $120M For Liver Disease Drug Development
- Investors Sue Infertility Co. OvaScience To Stop Merger Plan
- World Wide Weed: Best Practices For Internet Cannabis Ads
- When Regulatory Standards And Truth In Advertising Collide
- Time To Reclaim Wellness For All Lawyers
- Kavanaugh Fallout Fuels GOP's Senate Expansion
- Dems Pump Brakes On Trump Agenda With House Win
- Senate Republican Win Cements Trump's Judicial Makeover
- Voting Machine Critics Tout Low-Tech Fix For Hacking Fears
- FDA Warning Wire: No Risk Info On Drug Webpage
- Express Scripts Defends Fee Ask After Pharmacy Sanctioned
- Fresenius Fights Kyle Bass Diprivan Challenge At Fed. Circ.
- Endocyte's $2.1B Sale To Novartis 'Unfair' To Investors: Suit
- Fed. Circ. Urged Not To Stay Immunity Ruling For Appeal
- Orencia Patent Appeal Not Moot, Momenta Tells Fed. Circ.
- Insurer Needn't Cover Landlord In Suit Over CO Leak
- Aveo CFO Told Investors 'Half The Story,' Jury Hears
- DST Hit With ERISA Suit Over Valeant Stock Drop
- 1st Circ. Mulls Boston NPR Push For Release Of Juror IDs
- J&J Talc Caused Atty's Fatal Mesothelioma, 2nd Jury Hears
- Jury Award Doubled To $268M In Hearing Aid IP Case
- Invisalign Maker Says Rival Is Infringing Scanner Cover IP
- Ex-Akebia Statistician Gets 3 Years For Insider Trading
- Deals Rumor Mill: Sears, Tata, Medacta
- Humana Seeks Case's Inclusion In Generic Price-Fixing MDL
- Opioid Distributors Seek Ohio High Court Input On State Law
- Teva Suit Built On 'Tottering Tower Of Conjecture,' FDA Says
- Key Figure Gets Prison For $3M Insider Trading Scheme
- Vet Products Co. To Pay $6.75M Over Unwanted Faxes
- Software Startup Leads 3 IPO Launches Totaling $535M
- Jury Picked For Ex-Drug Co. CFO's Securities Fraud Trial
- Fears Nachawati Adds Ex-DOJ Opioid Specialist In Dallas
- Supreme Court Rejects Ex-InterMune CEO's Conviction Appeal
- Medtronic Fires Back In Ex-PTAB Chief's Gay Bias Suit
- Boies Schiller Stuck On Express Scripts Breach Trial
- Roundup Verdict Points To Jury Realities In Product Cases
- Spotlight On Private Antitrust Enforcement At Seoul Forum
- 3 Firms Lead Pack In Rocky October For IPOs
- Hagens Berman Seeks Lead Role In Intuniv Pay-For-Delay Suit
- DaVita Settles After $384M Verdict In Patient Danger Suits
- Pa. Panel Won't DQ Goodwin Procter In Teva Coverage Row
- Pharmacy Co. Slams EHealthline's Bid To Pause $3.5M Award
- Zetia MDL Buyers Maintain Merck's Generic Deal Was Illegal
- Damages Forfeited In Opioid MDL Bellwethers, Drug Cos. Say
- Ex-Genentech Engineer Pleads Not Guilty To Hacking, IP Theft
- Settlement Reached In Stryker Hip Replacement Suits
- NJ Court Kicks Stendra Patent Case To Texas
- What We Heard At The FTC Hearings: Days 6 And 7
- Pa. Justices Urged To Reject Limit On Risperdal Suit Window
- Deals Rumor Mill: Pfizer, Apple, Ping An
- Covington Advises Illumina's $1.2B Pacific Biosciences Buy
- Celgene's Bid To Trim Drug Monopoly Suit Denied
- Trump's Point Person On Drug Prices Dies
- PTAB Says Rituxan Patent Challenged By Pfizer Is Obvious
- Aveo Stock Plunge Fair Game When Ex-CFO Stands Trial
- Boies Schiller Can't Ditch Clients Before Trial: Express Scripts
- Sanofi Wants Claims Against Mylan Out Of EpiPen MDL
- Pharma Co. Cleared To Use Lender Cash In Ch. 11
- AbbVie Looks To Ditch FCA Suit Alleging Humira Kickbacks
- FDA Steps Up Its Focus On Medical Device Cybersecurity
- CMS Drug Price Proposal Would Harm Patients, Providers
- Jenner, Gibson Guide $630M Sale Of Water Co. To PE Shop